Ximelagatran Compared with Warfarin for the Prevention of Systemic Embolism and Stroke. An Imputed Placebo Analysis

Author： Berry Colin   Norrie John   McMurray John  

Publisher： Springer Publishing Company

ISSN： 0920-3206

Source： Cardiovascular Drugs and Therapy, Vol.19, Iss.2, 2005-03, pp. : 149-151

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation†

By Garnock-Jones Karly P.  

Drugs & Aging, Vol. 28, Iss. 5, 2011-05 ,pp. : 415-419

Adis International

Access to resources Recommend Favorite

Ximelagatran simplifies stroke prevention for patients with AF

By  

Inpharma, Vol. 1, Iss. 1419, 2004-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Ximelagatran Cost Effectiveness for Stroke Prevention in Atrial Fibrillation

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 35, Iss. 4, 2005-12 ,pp. : 279-283

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dabigatran Etexilate: A Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

By Garnock-Jones Karly P.  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 1, 2011-02 ,pp. : 57-72

Adis International

Access to resources Recommend Favorite

Dabigatran Etexilate: A Pharmacoeconomic Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

By McKeage Kate  

PharmacoEconomics, Vol. 30, Iss. 9, 2012-09 ,pp. : 841-855

Adis International

Access to resources Recommend Favorite